#

Chronic Idiopathic Urticaria

  • Compensation to be determined
  • 13 visits (enrollment open)
#

Between 18 - 75 Years

#
Male or Female
#
Smoker & Non-Smoker

Description

The study is a global, multicenter, randomized, double-blind, active-controlled, parallel-group study to evaluate the comparative efficacy, safety, immunogenicity, and interchangeability of ADL-018 with US-Xolair® administered subcutaneously (SC) as an add-on therapy for the treatment of adult patients aged 18 to 75 who have been diagnosed with refractory CIU and who remain symptomatic despite standarddosed H1 antihistamine treatment. The study will consist of 4 distinct study periods over a time period of 42 weeks.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

Depression (ALTO)

  • Compensation to be determined
  • The total number of visits is 12 with 5 visits in clinic and 7 remote visits
#
Between 18 - 65 Years

#
Male or Female
#
Smoker & Non-Smoker
#

Chronic Idiopathic Urticaria

  • Compensation to be determined
  • 13 clinic visits including 3 safety follow-up visits
#
Between 18 - 75 Years

#
Male or Female
#
Smoker & Non-Smoker
#

Ulcerative Colitis (IQVIA)

  • Compensation to be determined
  • clinic visits 10
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved